Madrigal Pharmaceuticals (MDGL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Liver Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 7.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 18.57% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus
- Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run
- Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?
- Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
- Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
- Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
- Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Madrigal Pharmaceuticals.
Full MDGL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.